Read Carlito Lebrilla's Blog Post on "Glycans and Cancer"

InterVenn Blog

February 22, 2019
By Carlito Lebrilla

Our body is made up of proteins. Measuring the abundances of these proteins has been the primary goal of scientists because they give us a way of understanding diseases. More careful analysis of proteins reveals that that no matter how similar proteins seem, they are not really the same. Proteins become modified through a process of post translational modification to yield the fine tuning of the proteins function.  One of the most common modification is the addition of short sugar chains called glycans. There are several places that glycans can attach on proteins. And even on a single site of attachment, a protein may have different copies of glycans to give different versions of the same protein. It turns out that glycans are very important for the proteins’ functions. Some function of glycans include changing the proteins structure, making the protein more interactive with other proteins, and allowing the protein […]

December 12, 2018
By Aldo Carrascoso

We envision a time when cancer is no longer a problem – and all disease a mere nuisance. In this time, disease is holistically understood enough for it to be controlled and manipulated to benefit all. We envision a place where previously unrelated disciplines intersect and “interdepend” in a singular pursuit of a solution. In this place, “extremely hard but not ultimately impossible” approaches are embraced, and given serious scientific, social and economic consideration. InterVenn wasn’t started because it was “novel” or “cool”, it wasn’t an intellectual exercise nor was it in because of a trend. It was started in pursuit of a universal problem that has seen its fair share of the same solutions time and time again. Ignited by incredible need and frustration, and fueled by deep scientific rigor, we exist today to revisit the health-disease spectrum with an unprecedented focus on the epi-proteome (glycoproteomics) and how we […]

December 12, 2018
By Carlito Lebrilla Carolyn Bertozzi Lieza Danan

Most proteomic endeavors have focused on identifying and quantifying expression levels of low abundance proteins. These queries are necessary but not sufficient, as the assessment of proteins is incomplete without simultaneously shining light on post-translational modifications (PTMs) and how they augment the proteome. PTMs decorate translated proteins in a dynamic fashion, and the multitude of possible forms constitute the “epi-proteome,” in much the same way as epigenetic marks and DNA define the epigenome. The most information-dense PTM is glycosylation, where various glycans (oligosaccharides) are attached to amino acid residues in a translated protein. One of four major classes of biological macromolecules found in all lifeforms, glycans play a major role in regulating protein folding, signaling, and numerous cellular functions. Aberrant glycosylation is increasingly being recognized in conditions such as cancer, inflammation, autoimmunity and neurodegenerative diseases. The science of how and why glycosylation introduces microheterogeneity within individual proteins has been on […]

December 12, 2018
By Aldo Carrascoso

Funding to accelerate InterVenn’s development of its AI-driven mass spectrometry platform that measures glycoproteomic markers that have been strongly linked to tumor development and progression. Redwood City, Calif, December 12, 2018: — InterVenn BioSciences, a life sciences and technology company developing an AI-driven mass spectrometry platform, announced today an institutional investment of $9.4 million led by seasoned biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV. The financing will be used to develop the company’s first product, a blood-based ovarian cancer diagnostic. Jenny Rooke, Ph.D., founder and managing director at Genoa Ventures, and Adam D’Augelli, partner at True Ventures, will join InterVenn’s board of directors. Sunil Dhaliwal, general partner at Amplify Partners, will join as a board observer. Glycoproteomics, an emerging field combining proteomics and glycomics, can help with better biomarker and target discovery, but produces an enormous amount of data in minutes […]